Gilead Sciences (GILD) PT Lowered to $64 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini lowered the price target on Gilead Sciences (NASDAQ: GILD) to $64.00 (from $74.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
